Terms: = Brain cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Clinical Outcome
7 results:
1. Long-term clinical outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal cancer.
Tosi F; Sartore-Bianchi A; Lonardi S; Amatu A; Leone F; Ghezzi S; Martino C; Bencardino K; Bonazzina E; Bergamo F; Fenocchio E; Martinelli E; Troiani T; Siravegna G; Mauri G; Torri V; Marrapese G; Valtorta E; Cassingena A; Cappello G; Bonoldi E; Vanzulli A; Regge D; Ciardiello F; Zagonel V; Bardelli A; Trusolino L; Marsoni S; Siena S
Clin Colorectal Cancer; 2020 Dec; 19(4):256-262.e2. PubMed ID: 32919890
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value of kras Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract] [Full Text] [Related]
3. clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with kras-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B; Brambilla M; Cortellini A; De Giglio A; Ficorella C; Sidoni A; Bellezza G; Crinò L; Ludovini V; Baglivo S; Metro G; Chiari R
Clin Transl Oncol; 2020 May; 22(5):708-716. PubMed ID: 31332704
[TBL] [Abstract] [Full Text] [Related]
4. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract] [Full Text] [Related]
5. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in kras-Mutant Lung Adenocarcinoma.
Calles A; Sholl LM; Rodig SJ; Pelton AK; Hornick JL; Butaney M; Lydon C; Dahlberg SE; Oxnard GR; Jackman DM; Jänne PA
Clin Cancer Res; 2015 Jun; 21(12):2851-60. PubMed ID: 25737507
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to kras mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract] [Full Text] [Related]
7. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.
Ogino S; Lochhead P; Giovannucci E; Meyerhardt JA; Fuchs CS; Chan AT
Oncogene; 2014 Jun; 33(23):2949-55. PubMed ID: 23792451
[TBL] [Abstract] [Full Text] [Related]
